Diabetic neuropathy in animal models

Drug Discovery Today: Disease Models

Volumn 4, Issue 1, 2007, Pages 39-44

  Sigaudo Roussel, Dominique ^a   Fromy, Bérengère ^a   Saumet, Jean Louis ^b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; ANTIOXIDANT; C PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; GANGLIOSIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INOSITOL; INSULIN; LEPTIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SODIUM GLUCOSE COTRANSPORTER; STREPTOZOCIN; UNCLASSIFIED DRUG;

DIABETIC NEUROPATHY; DISEASE MODEL; GENE OVEREXPRESSION; GOTO KAKIZAKI RAT; HUMAN; HYPERALGESIA; HYPERGLYCEMIA; HYPOALGESIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NERVE CONDUCTION; NEUROFILAMENT; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOPHYSIOLOGY; REVIEW; TRANSGENIC MOUSE; ZUCKER DIABETIC FATTY RAT;

EID: 37349109249     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2007.09.005     Document Type: Review

References (40)

1. Hounsom L., and Tomlinson D.R. Does neuropathy develop in animal models?. Clin. Neurosci. 4 (1997) 380-389
2. Dobretsov M., et al. Early diabetic neuropathy: triggers and mechanisms. World J. Gastroenterol. 13 (2007) 175-191
3. Rees D.A., and Alcolado J.C. Animal models of diabetes mellitus. Diabet. Med. 22 (2005) 359-370
4. Sigaudo-Roussel D., et al. Early endothelial dysfunction severely impairs skin blood flow response to local pressure application in streptozotocin-induced diabetic mice. Diabetes 53 (2004) 1564-1569
5. Demiot C., et al. Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice. Cardiovasc. Res. 69 (2006) 245-252
6. Akkina S.K., et al. GDNF rescues nonpeptidergic unmyelinated primary afferents in streptozotocin-treated diabetic mice. Exp. Neurol. 167 (2001) 173-182
7. Christianson J.A., et al. Beneficial actions of neurotrophin treatment on diabetes-induced hypoalgesia in mice. J. Pain 4 (2003) 493-504
8. Demiot C., et al. Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes 55 (2006) 1478-1483
9. Kennedy J.M., and Zochodne D.W. Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage?. Diabetes 54 (2005) 830-837
10. Calcutt N.A., et al. Protection of sensory function in diabetic rats by Neotrofin. Eur. J. Pharmacol. 534 (2006) 187-193
11. Sima A.A., and Kamiya H. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann. N. Y. Acad. Sci. 1084 (2006) 235-249
12. Schmidt R.E., et al. Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J. Neuropathol. Exp. Neurol. 63 (2004) 450-460
13. Pieper G.M., et al. Decreased opioid-induced antinociception but unaltered G-protein activation in the genetic-diabetic NOD mouse. Eur. J. Pharmacol. 401 (2000) 375-379
14. Obrosova I.G., et al. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J. 19 (2005) 401-403
15. Gabra B.H., and Sirois P. Hyperalgesia in non-obese diabetic (NOD) mice: a role for the inducible bradykinin B1 receptor. Eur. J. Pharmacol. 514 (2005) 61-67
16. Gradin K.A., et al. Enhanced neuropeptide Y immunoreactivity and vasoconstriction in mesenteric small arteries from the early non-obese diabetic mouse. Eur. J. Pharmacol. 539 (2006) 184-191
17. Schmidt R.E., et al. Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy: a new experimental model of diabetic autonomic neuropathy. Am. J. Pathol. 163 (2003) 2077-2091
18. Li F., et al. Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol. Dis. 22 (2006) 669-676
19. Coppey L.J., et al. Changes in endoneurial blood flow, motor nerve conduction velocity and vascular relaxation of epineurial arterioles of the sciatic nerve in ZDF-obese diabetic rats. Diabetes Metab. Res. Rev. 18 (2002) 49-56
20. Oltman C.L., et al. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am. J. Physiol. Endocrinol. Metab. 289 (2005) E113-E122
21. Wada R., et al. Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for type 2 diabetes. Diabetes Metab. Res. Rev. 15 (1999) 332-337
22. Yagihashi S., et al. Peripheral neuropathy in selectively-inbred spontaneously diabetic rats: electrophysiological, morphometrical and freeze-replica studies. Tohoku J. Exp. Med. 138 (1982) 39-48
23. Suzuki K., et al. The significance of nerve sugar levels for the peripheral nerve impairment of spontaneously diabetic GK (Goto-Kakizaki) rats. Diabetes Res. 14 (1990) 21-25
24. Ueta K., et al. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci. 76 (2005) 2655-2668
25. Murakawa Y., et al. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab. Res. Rev. 18 (2002) 473-483
26. Miyasaka K., et al. Disturbance of response to acute thermal pain in naturally occurring cholecystokinin-a receptor gene knockout Otsuka Long-Evans Tokushima Fatty (OLETF) rats. J. Pharmacol. Sci. 101 (2006) 280-285
27. Nakamura J., et al. Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT. Life Sci. 60 (1997) 1847-1857
28. Kamenov Z., et al. Physiological characteristics of diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats. Methods Find. Exp. Clin. Pharmacol. 28 (2006) 13-18
29. Drel V.R., et al. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes 55 (2006) 3335-3343
30. Norido F., et al. Development of diabetic neuropathy in the C57BL/Ks (db/db) mouse and its treatment with gangliosides. Exp. Neurol. 83 (1984) 221-232
31. Underwood R.A., et al. Color subtractive-computer-assisted image analysis for quantification of cutaneous nerves in a diabetic mouse model. J. Histochem. Cytochem. 49 (2001) 1285-1291
32. Gibran N.S., et al. Diminished neuropeptide levels contribute to the impaired cutaneous healing response associated with diabetes mellitus. J. Surg. Res. 108 (2002) 122-128
33. Llewelyn J.G., et al. Aldose reductase activity and myo-inositol levels in sciatic nerve and dorsal root ganglia of the diabetic mutant mouse [C57/BL/Ks (db/db)]. Metabolism 40 (1991) 1084-1087
34. Yagihashi S., et al. Pathology and pathogenetic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms. Diabetes Res. Clin. Pract. 77 (2007) S184-S189
35. Uehara K., et al. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 53 (2004) 3239-3247
36. Ho E.C., et al. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 55 (2006) 1946-1953
37. Song Z., et al. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol. Cell Neurosci. 23 (2003) 638-647
38. Zochodne D.W., et al. Accelerated diabetic neuropathy in axons without neurofilaments. Brain 127 (2004) 2193-2200
39. Chen Y.S., et al. Noninvasive monitoring of diabetes-induced cutaneous nerve fiber loss and hypoalgesia in thy1-YFP transgenic mice. Diabetes 54 (2005) 3112-3118
40. Plum L., et al. Transgenic and knockout mice in diabetes research: novel insights into pathophysiology, limitations, and perspectives. Physiology (Bethesda) 20 (2005) 152-161